...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients
【24h】

B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: A therapeutic approach for APECED patients

机译:Aire缺陷小鼠发展多器官自发炎症反应需要B细胞:APECED患者的治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

Autoimmune regulator (Aire)-deficient mice and humans have circulating autoantibodies against a multitude of organs and multiorgan autoinflammatory infiltrates. It is not known to what extent autoantibodies or their source, B lymphocytes, are required for disease onset or progression. We show in this research that B cells must be present for Aire-deficient mice to develop fulminant infiltrates. We found no evidence that autoantibodies were directly pathogenic; rather, B cells appeared to play a critical early role in T cell priming or expansion. A therapeutic reagent directed against B cells, Rituximab, induced remission of the autoimmune disease in Aire-deficient mice, raising the hope of applying it to human patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
机译:缺乏自身免疫调节剂(Aire)的小鼠和人类具有针对多种器官和多器官自身炎性浸润的循环自身抗体。尚不清楚疾病发作或进展所需的自身抗体或其来源B淋巴细胞的程度。我们在这项研究中表明,对于Aire缺陷型小鼠,必须出现B细胞才能发展暴发性浸润。我们没有发现证据表明自身抗体是直接致病的。相反,B细胞似乎在T细胞启动或扩增中起着关键的早期作用。一种针对B细胞的治疗药物,利妥昔单抗(Rituximab),可在Aire缺陷小鼠中缓解自身免疫病,从而有望将其应用于患有自身免疫性多内分泌病,念珠菌病,外胚层营养不良(APECED)的人类患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号